Pharma channel feed

Back in busi­ness af­ter a spell in lim­bo, Iron­shore says it has raised $143M for AD­HD drug roll­out

7 years ago

Bio­gen’s big break­through drug Spin­raza runs in­to a bar­ri­er as NICE turns thumbs down on re­im­burse­ment

7 years ago

CEO in­ter­rupt­ed: No­var­tis chief Narasimhan looks to new ethics czar to clean up af­ter the lin­ger­ing Co­hen mess

7 years ago
People

Bay­er tar­gets COPD in a new dis­cov­ery al­liance with Hap­lo­gen, Evotec

7 years ago
R&D

Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

7 years ago
R&D
Cell/Gene Tx

FDA drafts guid­ance on seam­less clin­i­cal tri­als for can­cer drug de­vel­op­ers

7 years ago

Rac­ing No­var­tis on Eylea ri­val, the FDA trips up Re­gen­eron at the fin­ish line

7 years ago

Once stiff-armed at the FDA, new man­age­ment of­fers Am­i­cus a warm em­brace for Galafold -- priced at $315,000

7 years ago

Gung ho: Al­ny­lam lands his­toric FDA OK on patisir­an, revving up the first glob­al roll­out for an RNAi break­through

7 years ago

Trump ad­min­is­tra­tion sinks teeth in­to par­ing down drug prices, on 5 key points

7 years ago

Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

7 years ago
China

Bio­gen's high-stakes Alzheimer's gam­ble is be­ing roast­ed by the ex­perts. Is the amy­loid be­ta the­o­ry dead?

7 years ago
R&D

FDA ap­proves first gener­ic drug to re­ceive CGT des­ig­na­tion

7 years ago

Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

7 years ago

Ky­owa Kirin gets some added love from the FDA, win­ning their sec­ond drug OK in 4 months

7 years ago

Cell­tri­on re­ceives Form 483 for trou­bled Ko­re­an site

7 years ago

Trump ad­min­is­tra­tion opens the door to low­er drug prices as Medicare Ad­van­tage plans are pushed to step ther­a­py ap­proach

7 years ago

14-year-old par­tial hold comes back to haunt Gem­phire, bat­ter­ing shares and wreck­ing time­lines

7 years ago
R&D

New re­port sin­gles out Big Phar­ma play­ers for ring­ing their block­busters with patents while hik­ing prices for years

7 years ago

Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

7 years ago
R&D

Block­buster dreams quashed, Iron­wood drops As­traZeneca's $1.3B gout drug dis­as­ter

7 years ago

With PD-1 OK loom­ing, Re­gen­eron antes $100M on blue­bird al­liance for next-gen TCR cell ther­a­py pact

7 years ago

Roche gets some reg­u­la­to­ry love for its break­through quest on a PhI­II Hunt­ing­ton's drug

7 years ago

EMA: More staff than an­tic­i­pat­ed quit ahead of Brex­it re­lo­ca­tion

7 years ago
First page Previous page 291292293294295296297 Next page Last page
A service from the Financial Times